secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0000950170-24-080546
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028
--------------------------------------------------------------------------------

- Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
- Additional $25M available upon milestone: execution of first line pivotal Phase 3 trial of palazestrant with ribociclib.
- Further $50M may be available at bank's discretion; maturity extended 11 months to July 1, 2028.
- No funds drawn under the loan agreement to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/0000950170-24-080546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/olma-20240628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-080546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer